Loss of Rap1GAP in Papillary Thyroid Cancer
- 1 March 2009
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (3), 1026-1032
- https://doi.org/10.1210/jc.2008-1042
Abstract
Context: Rap1 GTPase-activating protein (GAP) regulates the activity of Rap1, a putative oncogene. We previously reported Rap1GAP was highly expressed in normal human thyroid cells and decreased in five papillary thyroid carcinomas (PTCs). Objectives: To confirm the significance of these findings, we analyzed Rap1GAP expression in a larger set of benign tumors (adenomas and hyperplastic nodules) and PTCs. We determined whether the presence of the BRAFV600E mutation or allelic loss of Rap1GAP related to changes in Rap1GAP protein expression. To determine the consequences of Rap1GAP loss, we targeted Rap1GAP in culture using small interfering RNA. Design, Patients, and Methods: A highly specific Rap1GAP antibody was applied to sections of 55 human thyroid tissues. Genomic DNA was analyzed for the presence of the BRAFV600E mutation, and loss of Rap1GAP. Rap1GAP expression in rat thyroid cells was abolished using small interfering RNA. Results: We observed that down-regulation of Rap1GAP in benign lesions and PTCs was common. Rap1GAP expression was more severely decreased in PTCs. Loss of Rap1GAP expression was observed in multiple histological variants of PTCs. Approximately 20% of PTCs and adenomas exhibited allelic loss of Rap1GAP. Loss of Rap1GAP was not associated with the presence of the BRAFV600E mutation. In vitro, loss of Rap1GAP was sufficient to increase Rap1 activity in thyroid cells. Conclusions: These data indicate that loss of Rap1GAP is a frequent event in PTC. The more frequent and greater down-regulation of Rap1GAP in PTCs compared with adenomas suggests a role for Rap1GAP depletion in the progression of human thyroid tumors, possibly through unrestrained Rap activity.Keywords
This publication has 31 references indexed in Scilit:
- Faculty Opinions recommendation of High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.Published by H1 Connect ,2013
- A Genecentric Human Protein Atlas for Expression Profiles Based on AntibodiesMolecular & Cellular Proteomics, 2008
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient miceCancer Cell, 2003
- Does Rap1 deserve a bad Rap?Trends in Biochemical Sciences, 2003
- Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.2003
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase.2002
- On the mitogenic properties of Rap1b: cAMP-induced G 1 /S entry requires activated and phosphorylated Rap1bProceedings of the National Academy of Sciences of the United States of America, 2002
- The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilinProceedings of the National Academy of Sciences of the United States of America, 2000